PLAINSBORO, N.J., Aug 16, 2007 (PrimeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it has signed an agreement with InteliFUSE, Inc. to distribute its patented shape memory implant and activation system in the U.S. and Canada and will showcase the AEON Shape Memory Implant at 2007 American Podiatric Medical Association (APMA) Annual Scientific Meeting, Philadelphia, Pennsylvania, August 16-19, 2007. The AEON Shape Memory Implant, a nitinol "smart" shape memory staple, has an FDA clearance for use in many orthopaedic indications, including surgeries for the foot, ankle, hand and wrist, as an alternative to rods, nails, screws and wires. The AEON Shape Memory Implant will be available in sizes, gauges and designs appropriate to several fixation and fusion indications.

Based on available procedural data, Integra estimates that the AEON Memory Staple can be used in over 600,000 extremity reconstructive procedures annually. It will be sold by Integra's Extremity Reconstruction Sales organization, which includes over 75 U.S. sales specialists who focus on lower extremity fixation, upper extremity fixation, wound repair, tendon protection, and peripheral nerve repair/protection.

The U.S. Naval Ordnance Research Laboratories developed Nitinol in the early 1960s. First used by the Navy and subsequently by NASA and aircraft manufacturers, shape memory alloys eventually migrated to medicine. Nitinol's ability to assume one shape when cooled and another when heated makes it a useful material for orthopedic procedures that require bone growth and fusion.

Disposable electrodes quickly heat the AEON implant to non-necrotic temperatures, allowing the AEON implant to apply compression force through the bone fragments. Internal body temperature keeps the staple in its active state indefinitely, enabling the implant to apply continuous dynamic compression, which stimulates the body's natural response to grow bone (osteogenesis) and fuse fractures. Because the AEON implant is smaller and less bulky than many other fixation devices, benefits may also include less patient trauma and scarring, quicker procedure times and speedier post-operative recovery.

"We're very pleased to introduce the AEON Shape Memory Implant to the orthopedic community," said Robert Paltridge, Integra's President, Extremity Reconstruction Division. "Integra's customers will have access to a device that offers a simple and efficient method of applying continuous dynamic compression designed to promote bone fusion. The AEON staple is a natural complement to our growing portfolio of extremity reconstruction products."

"We are delighted that Integra's Extremity Reconstruction Division will distribute our shape memory implant and warming technologies in North America," said Eugene A. ("Chip") Antoine, Jr., InteliFUSE's President and CEO. "Our alliance, which combines Integra's excellent sales and marketing capabilities with our proven technology, will speed surgeons' access to this exciting product line."

InteliFUSE, Inc., incorporated in Delaware and headquartered in New Orleans, Louisiana, was founded to design, develop and market a new generation of surgical implants for the $5 billion orthopaedic fixation implant market and has acquired multiple patents and intellectual property related to the use of shape memory technology for bone fracture fixation/fusion and bone remodeling. InteliFUSE has several new patents pending. Please visit its website at www.intelifuse.com.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at www.Integra-LS.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the AEON Shape Memory Implant. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use this product may affect the prospects for its use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the Risk Factors included in Item lA of Integra's Annual Report on Form 10-K for the year ended December 31, 2006, and information contained in subsequent filings with the Securities and Exchange Commission, could affect actual results.

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation John B. Henneman, III, Executive Vice President, Chief Administrative Officer (609) 936-2481 jhenneman@Integra-LS.com Gianna Sabella Public Relations Manager (609) 936-2389 gsabella@Integra-LS.com



^© Copyright 2007 PrimeNewswire, Inc. All rights reserved.

News Provided by COMTEX